Previous 10 | Next 10 |
On Monday, Twist Bioscience Corp ( NASDAQ:TWST ) shares declined by more than 8% after announcing its fiscal fourth-quarter results. The company reported its most recent quarterly results before markets opened, missing the consensus analyst expectation on earnings per share. However...
The following slide deck was published by Twist Bioscience Corporation in conjunction with their 2021 Q4 earnings call. For further details see: Twist Bioscience Corporation 2021 Q4 - Results - Earnings Call Presentation
Twist Bioscience (NASDAQ:TWST) announced a definitive agreement to acquire Abveris, a privately held firm focused on in vivo antibody discovery services, for a total consideration of up to $190M. Formerly known as AbX Biologics, Abveris leverages a family of hyperimmune mouse models...
Twist Bioscience (NASDAQ:TWST): Q4 GAAP EPS of $0.84 beats by $1.63. Revenue of $37.95M (+17.0% Y/Y) beats by $1.69M. Press Release Fiscal 2022 Financial Guidance: Revenue is expected in the range of $173 million to $181 million vs a consensus of $171.09M without Abveris and $183 m...
-- Record Revenues in Fiscal 2021 of $132.3M; Increase of 47% over $90.1M in Fiscal 2020 -- -- Growth Driven by Strength in SynBio, NGS, Biopharma Businesses -- -- Expect Revenue of $183M to $193M for Fiscal 2022 -- Twist Bioscience Corporation (NASDAQ: TWST), a company ...
-- Acquisition Will Add In Vivo Antibody Discovery Platform – -- Conference Call at 8:00am ET -- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platf...
Twist Bioscience (NASDAQ:TWST) is scheduled to announce Q4 earnings results on Monday, November 22nd, before market open. The consensus EPS Estimate is -$0.81 (-50.0% Y/Y) and the consensus Revenue Estimate is $36.26M (+11.8% Y/Y). Twist beat revenue estimates in Q3, jumping 65.1% Y/Y. It rai...
Pharma/biotechnology is the most attractive healthcare subsector. Life science tools have performed the best in one year, but are overvalued now. Focus on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For November
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Invetx, a pioneer in protein-based therapeutics for animal health, today announced an extension to their existing antib...
-- Executive Leadership Team Established with Demonstrated Success in Clinical, Regulatory and Commercial Development -- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon plat...
News, Short Squeeze, Breakout and More Instantly...
Twist Bioscience Corporation Company Name:
TWST Stock Symbol:
NASDAQ Market:
Twist Bioscience Corporation Website:
Pure Biologics’ exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumors Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today a...
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 th...
Express Genes enable faster turnaround times Twist Express Antibodies, CHO starting at 13 business days Twist Express Antibodies, HEK293 starting at 10 business days Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of ...